File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Non-small cell lung cancer: Clinical practice guidelines in oncology

TitleNon-small cell lung cancer: Clinical practice guidelines in oncology
Authors
Ettinger, David S.Akerley, WallaceBorghaei, HosseinChang, Andrew C.Cheney, Richard T.Chirieac, Lucian R.D'Amico, Thomas A.Demmy, Todd L.Ganti, Apar Kishor P.Govindan, RamaswamyGrannis, Frederic W.Horn, LeoraJahan, Thierry M.Jahanzeb, MohammadKessinger, AnneKomaki, RitsukoKong, Feng MingKris, Mark G.Krug, Lee M.Lennes, Inga T.Loo, Billy W.Martins, RenatoO'Malley, JanisOsarogiagbon, Raymond U.Otterson, Gregory A.Patel, Jyoti D.Pinder-Schenck, Mary C.Pisters, Katherine M.Reckamp, KarenRiely, Gregory J.Rohren, EricSwanson, Scott J.Wood, Douglas E.Yang, Stephen C.Hughes, MirandaGregory, Kristina M.
Issue Date2012
Citation
JNCCN Journal of the National Comprehensive Cancer Network, 2012, v. 10, n. 10, p. 1236-1271 How to Cite?
DOI: http://dx.doi.org/10.6004/jnccn.2012.0130
AbstractMost patients with non-small cell lung cancer (NSCLC) are diagnosed with advanced cancer. These guidelines only include information about stage IV NSCLC. Patients with widespread metastatic disease (stage IV) are candidates for systemic therapy, clinical trials, and/or palliative treatment. The goal is to identify patients with metastatic disease before initiating aggressive treatment, thus sparing these patients from unnecessary futile treatment. If metastatic disease is discovered during surgery, then extensive surgery is often aborted. Decisions about treatment should be based on multidisciplinary discussion. © JNCCN-Journal of the National Comprehensive Cancer Network.
Persistent Identifierhttp://hdl.handle.net/10722/266948
ISSN
1540-1405
2021 Impact Factor: 12.693
2020 SCImago Journal Rankings: 3.707
ISI Accession Number ID
WOS:000309901900007

 

DC FieldValueLanguage
dc.contributor.authorEttinger, David S.-
dc.contributor.authorAkerley, Wallace-
dc.contributor.authorBorghaei, Hossein-
dc.contributor.authorChang, Andrew C.-
dc.contributor.authorCheney, Richard T.-
dc.contributor.authorChirieac, Lucian R.-
dc.contributor.authorD'Amico, Thomas A.-
dc.contributor.authorDemmy, Todd L.-
dc.contributor.authorGanti, Apar Kishor P.-
dc.contributor.authorGovindan, Ramaswamy-
dc.contributor.authorGrannis, Frederic W.-
dc.contributor.authorHorn, Leora-
dc.contributor.authorJahan, Thierry M.-
dc.contributor.authorJahanzeb, Mohammad-
dc.contributor.authorKessinger, Anne-
dc.contributor.authorKomaki, Ritsuko-
dc.contributor.authorKong, Feng Ming-
dc.contributor.authorKris, Mark G.-
dc.contributor.authorKrug, Lee M.-
dc.contributor.authorLennes, Inga T.-
dc.contributor.authorLoo, Billy W.-
dc.contributor.authorMartins, Renato-
dc.contributor.authorO'Malley, Janis-
dc.contributor.authorOsarogiagbon, Raymond U.-
dc.contributor.authorOtterson, Gregory A.-
dc.contributor.authorPatel, Jyoti D.-
dc.contributor.authorPinder-Schenck, Mary C.-
dc.contributor.authorPisters, Katherine M.-
dc.contributor.authorReckamp, Karen-
dc.contributor.authorRiely, Gregory J.-
dc.contributor.authorRohren, Eric-
dc.contributor.authorSwanson, Scott J.-
dc.contributor.authorWood, Douglas E.-
dc.contributor.authorYang, Stephen C.-
dc.contributor.authorHughes, Miranda-
dc.contributor.authorGregory, Kristina M.-
dc.date.accessioned2019-01-31T07:20:04Z-
dc.date.available2019-01-31T07:20:04Z-
dc.date.issued2012-
dc.identifier.citationJNCCN Journal of the National Comprehensive Cancer Network, 2012, v. 10, n. 10, p. 1236-1271-
dc.identifier.issn1540-1405-
dc.identifier.urihttp://hdl.handle.net/10722/266948-
dc.description.abstractMost patients with non-small cell lung cancer (NSCLC) are diagnosed with advanced cancer. These guidelines only include information about stage IV NSCLC. Patients with widespread metastatic disease (stage IV) are candidates for systemic therapy, clinical trials, and/or palliative treatment. The goal is to identify patients with metastatic disease before initiating aggressive treatment, thus sparing these patients from unnecessary futile treatment. If metastatic disease is discovered during surgery, then extensive surgery is often aborted. Decisions about treatment should be based on multidisciplinary discussion. © JNCCN-Journal of the National Comprehensive Cancer Network.-
dc.languageeng-
dc.relation.ispartofJNCCN Journal of the National Comprehensive Cancer Network-
dc.titleNon-small cell lung cancer: Clinical practice guidelines in oncology-
dc.typeArticle-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.6004/jnccn.2012.0130-
dc.identifier.pmid23054877-
dc.identifier.scopuseid_2-s2.0-84870996017-
dc.identifier.volume10-
dc.identifier.issue10-
dc.identifier.spage1236-
dc.identifier.epage1271-
dc.identifier.eissn1540-1413-
dc.identifier.isiWOS:000309901900007-
dc.identifier.issnl1540-1405-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats